Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LADLY ABRAHAM

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1972537090
CMS profile
316423
Location
CONWAY, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$115,261.70

258 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 6; records 51–100 of 258 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LADLY ABRAHAM

NPI 1972537090 · CMS profile ID 316423

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

CONWAY, AR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 6; records 51–100 of 258 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1972537090?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LADLY ABRAHAM, NPI 1972537090, CMS profile ID 316423. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 258 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1972537090?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). LADLY ABRAHAM, NPI 1972537090, CMS profile ID 316423. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 258 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1972537090?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
LADLY ABRAHAM, NPI 1972537090, CMS profile ID 316423, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 258 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1972537090?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

258 matching records · $115,261.70 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 258 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 258.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Regeneron Healthcare Solutions, Inc. $98.5410/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113993557 CMS
Mylan Specialty L.P. $37.6010/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147284604 CMS
Mylan Specialty L.P. $21.6010/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147284608 CMS
Mylan Specialty L.P. $3,738.0010/05/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147284658 CMS
Mylan Specialty L.P. $441.3610/05/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147284676 CMS
Mylan Specialty L.P. $51.2010/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147284692 CMS
AstraZeneca Pharmaceuticals LP $3,400.0010/01/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105751277 CMS
Takeda Pharmaceuticals U.S.A., Inc. $18.9810/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137459996 CMS
United Therapeutics Corporation $20.4309/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149444402 CMS
Regeneron Healthcare Solutions, Inc. $20.1909/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113993555 CMS
INTUITIVE SURGICAL, INC. $72.5409/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137260647 CMS
Bayer Healthcare Pharmaceuticals Inc. $200.0009/23/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086133006 CMS
GlaxoSmithKline, LLC. $3,900.0009/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116092892 CMS
GlaxoSmithKline, LLC. $19.3409/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116420535 CMS
Actelion Pharmaceuticals US, Inc. $120.6909/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078863843 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.1809/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118256636 CMS
Electromed, Inc. $25.9509/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137875695 CMS
GlaxoSmithKline, LLC. $12.3709/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116660043 CMS
AstraZeneca Pharmaceuticals LP $3,400.0009/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105768468 CMS
AstraZeneca Pharmaceuticals LP $121.8209/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105844355 CMS
AstraZeneca Pharmaceuticals LP $1,160.7409/17/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105875835 CMS
GlaxoSmithKline, LLC. $1.5909/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116070141 CMS
GlaxoSmithKline, LLC. $12.2309/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116384820 CMS
Mallinckrodt Hospital Products Inc. $26.1209/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145044245 CMS
Electromed, Inc. $9.9009/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137875691 CMS
GENZYME CORPORATION $19.9209/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139688376 CMS
GlaxoSmithKline, LLC. $78.9709/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116190122 CMS
GlaxoSmithKline, LLC. $965.5709/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116319246 CMS
Actelion Pharmaceuticals US, Inc. $26.4309/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078863811 CMS
GlaxoSmithKline, LLC. $115.5909/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116611116 CMS
Mylan Specialty L.P. $19.4409/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147296453 CMS
Vifor Pharma, Inc. $18.9809/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124055711 CMS
Amgen Inc. $17.9309/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111508515 CMS
AstraZeneca Pharmaceuticals LP $936.2809/05/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104517486 CMS
AstraZeneca Pharmaceuticals LP $124.9709/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104704925 CMS
AstraZeneca Pharmaceuticals LP $3,750.0008/29/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104287596 CMS
Baxter Healthcare $23.6208/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118286547 CMS
GlaxoSmithKline, LLC. $120.5808/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116661617 CMS
Vifor Pharma, Inc. $18.6408/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1124048543 CMS
Regeneron Healthcare Solutions, Inc. $27.6608/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113993553 CMS
GlaxoSmithKline, LLC. $1.2308/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116280015 CMS
AstraZeneca Pharmaceuticals LP $16.8108/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104343340 CMS
GlaxoSmithKline, LLC. $12.2308/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116548257 CMS
GlaxoSmithKline, LLC. $4,550.0008/19/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116667239 CMS
AstraZeneca Pharmaceuticals LP $3,400.0008/16/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104466354 CMS
Takeda Pharmaceuticals U.S.A., Inc. $16.3308/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137459992 CMS
Actelion Pharmaceuticals US, Inc. $22.2508/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078863815 CMS
AstraZeneca Pharmaceuticals LP $1,048.5108/14/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104313986 CMS
AstraZeneca Pharmaceuticals LP $2,550.0008/14/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104744875 CMS
AstraZeneca Pharmaceuticals LP $24.9708/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105604139 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $55,976.70 243
PY2020 $11,873.95 143
PY2021 $16,283.65 151
PY2022 $14,340.81 160
PY2023 $88,375.29 199
PY2024 $115,261.70 258
PY2025 $68,596.81 194

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $11,914.21 41
PY2023 Principal investigator $7,107.84 14
PY2022 Principal investigator $22,482.59 38
PY2021 Principal investigator $35,091.00 17
PY2019 Principal investigator $73,421.28 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

41 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Insmed, Inc. $137.28 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067591622
Principal investigator 1 Insmed, Inc. $125.40 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067591624
Principal investigator 1 Insmed, Inc. $125.40 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067591626
Principal investigator 1 Insmed, Inc. $99.48 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067591628
Principal investigator 1 Insmed, Inc. $51.60 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067591630
Principal investigator 1 Insmed, Inc. $130.80 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067591632
Principal investigator 1 Insmed, Inc. $51.60 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067591634
Principal investigator 1 Insmed, Inc. $6.00 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067597010
Principal investigator 1 Insmed, Inc. $2.64 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067597012
Principal investigator 1 Insmed, Inc. $136.56 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067597014
Principal investigator 1 Insmed, Inc. $195.60 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067597016
Principal investigator 1 Insmed, Inc. $121.80 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067597018
Principal investigator 1 Insmed, Inc. $43.20 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067597020
Principal investigator 1 Insmed, Inc. $137.28 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067597022
Principal investigator 1 Insmed, Inc. $127.80 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067597024
Principal investigator 1 Insmed, Inc. $51.60 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067597026
Principal investigator 1 Insmed, Inc. $140.28 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067597028
Principal investigator 1 Insmed, Inc. $109.68 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067597030
Principal investigator 1 Insmed, Inc. $43.20 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067597032
Principal investigator 1 Insmed, Inc. $128.40 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067597034
Principal investigator 1 Insmed, Inc. $99.48 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602374
Principal investigator 1 Insmed, Inc. $136.56 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602376
Principal investigator 1 Insmed, Inc. $195.60 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602378
Principal investigator 1 Insmed, Inc. $109.68 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602380
Principal investigator 1 Insmed, Inc. $99.48 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602382
Principal investigator 1 Insmed, Inc. $109.68 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602384
Principal investigator 1 Insmed, Inc. $43.20 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602386
Principal investigator 1 Insmed, Inc. $121.80 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602388
Principal investigator 1 Insmed, Inc. $43.20 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602390
Principal investigator 1 Insmed, Inc. $121.80 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067602392
Principal investigator 1 Insmed, Inc. $136.56 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607764
Principal investigator 1 Insmed, Inc. $195.60 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607766
Principal investigator 1 Insmed, Inc. $43.20 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607768
Principal investigator 1 Insmed, Inc. $43.20 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607770
Principal investigator 1 Insmed, Inc. $127.80 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607772
Principal investigator 1 Insmed, Inc. $43.20 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607774
Principal investigator 1 Insmed, Inc. $43.20 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607776
Principal investigator 1 Insmed, Inc. $43.20 10/01/2024 Non-covered Recipient Entity
J&L Research LLC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study No dispute reported 06/30/2026 1067607778
Principal investigator 1 GlaxoSmithKline, LLC. $2,750.00 09/04/2024 Non-covered Recipient Entity
J AND L RESEARCH LLC
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 1127525076
Principal investigator 1 GlaxoSmithKline, LLC. $1,474.77 06/26/2024 Non-covered Recipient Entity
J AND L RESEARCH LLC
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 1127525078
Principal investigator 1 United Therapeutics Corporation $3,967.40 05/22/2024 Non-covered Recipient Entity
J&L Research LLC
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis No dispute reported 06/30/2026 1149624097